Is There a Role for Body Mass Index in the Assessment of Prostate Cancer Risk on Biopsy?

摘要

Purpose: We examine the role of body mass index in the assessment of prostate cancer risk.Materials and Methods: A total of 3,258 participants who underwent biopsy (including 1,902 men with a diagnosis of prostate cancer) were identified from the Selenium and Vitamin E Cancer Prevention Trial. The associations of body mass index with prostate cancer and high grade prostate cancer were examined using logistic regression, adjusting for age, race, body mass index adjusted prostate specific antigen, digital rectal examination, family history of prostate cancer, biopsy history, prostate specific antigen velocity, and time between study entry and the last biopsy.